Anti-Cyclin D1 antibody (ab61758)

Overview

• Product nameAnti-Cyclin D1 antibodySee all Cyclin D1 primary antibodies ...
• Description
  Rabbit polyclonal to Cyclin D1
• Tested applicationsELISA, IHC-P, WB more details
• Species reactivity
  Reacts with: Mouse, Human
  
• Immunogen

  Synthetic non-phosphopeptide derived from human Cyclin D1 around the phosphorylation site of threonine 286.

• Positive controlJurkat cell extract, treated with EGF (200ng/ml, 30mins), human brain tissue.

Properties

• FormLiquid
• Storage instructionsStore at -20°C. Stable for 12 months at -20°C
• Storage bufferPreservative: 0.02% Sodium Azide
  Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4
• Concentration information loading...
• PurityImmunogen affinity purified
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Cancer
  • Cell cycle
  • Cyclins
  • Cyclin D family

  • Epigenetics and Nuclear Signaling
  • Cell cycle
  • Cyclins
  • Cyclin D Family

  • Cell Biology
  • Cell Cycle
  • Cyclins
  • Cyclin D Family

Applications

Target

• FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
• Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
  Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
  Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
• Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
• Post-translational
  modificationsPhosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
  Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
• Cellular localizationNucleus.

Target information above from: UniProt accession P24385 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 595 Human
  • Entrez Gene: 12443 Mouse
  • Omim: 168461 Human
  • SwissProt: P24385 Human
  • SwissProt: P25322 Mouse
  • Unigene: 523852 Human
  • Unigene: 667996 Human
  • Unigene: 273049 Mouse

• Alternative names
  AI327039 antibodyB cell ccl/lymphoma 1 antibodyB cell CLL/lymphoma 1 antibody

  B cell leukemia 1 antibodyB cell leukemia 1 antibodyB cell lymphoma 1 protein antibodyB-cell lymphoma 1 protein antibodyBCL 1 antibodyBCL-1 antibodyBCL-1 oncogene antibodyBCL1 antibodyBCL1 oncogene antibodyCCND 1 antibodyCCND1 antibodyCCND1 protein antibodyCCND1/FSTL3 fusion gene, included antibodyCCND1/IGHG1 fusion gene antibodyCCND1/IGHG1 fusion gene, included antibodyCCND1/IGLC1 fusion gene, included antibodyCCND1/PTH fusion gene, included antibodyCCND1_HUMAN antibodycD1 antibodyCyl 1 antibodyD11S287E antibodyG1/S specific cyclin D1 antibodyG1/S-specific cyclin-D1 antibodyParathyroid adenomatosis 1 antibodyPRAD1 antibodyPRAD1 oncogene antibodyU21B31 antibody

  see all

Anti-Cyclin D1 antibody images

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Cyclin D1 antibody (ab61758)
  Human brain tissue stained with ab61758 at 1/50 dilution, with and without the immunising peptide.
• 

  Western blot - Cyclin D1 antibody (ab61758)
  All lanes : Anti-Cyclin D1 antibody (ab61758) at 1/500 dilution
  
  Lane 1 : extract from Jurkat cells, treated with EGF (200ng/ml, 30mins).
  Lane 2 : extract from Jurkat cells, treated with EGF (200ng/ml, 30mins), and the immunising peptide.
  
  
  Predicted band size : 31 kDa
  Observed band size : 31 kDa
  Additional bands at : 21 kDa. We are unsure as to the identity of these extra bands.